about
Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiencyReducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?Pharmacology of anticoagulants used in the treatment of venous thromboembolismDaily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications.Enoxaparin use in pregnancy: state of the art.Comparative glycomics using a tetraplex stable-isotope coded tag.Differentiation of the low-molecular-weight heparins.Rational design of low-molecular weight heparins with improved in vivo activity.Current and future antithrombotic agents in children.Treatment of deep vein thrombosis: what factors determine appropriate treatment?Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival.Drug insight: an overview of current anticoagulation therapy after heart valve replacement.Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and childrenCase files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose.Anticoagulant and antithrombotic drugs in pregnancy: what are the anesthetic implications for labor and cesarean delivery?Scientific considerations in the review and approval of generic enoxaparin in the United States.Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.A practical approach to the use of low molecular weight heparins in VTE treatment and prophylaxis in children and newborns.Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.Guideline adherence for antithrombotic therapy in acute coronary syndrome: an overview in Dutch hospitals.Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome.Renal function and thromboprophylaxis in critically ill patientsErratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism.Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina.Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.Low-dose aspirin plus low-molecular-weight heparin for the prevention of pre-eclampsia: yes, no or maybe.Drug delivery for bioactive polysaccharides to improve their drug-like properties and curative efficacy.Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects.Investigation of direct toxic and teratogenic effects of anticoagulants on rat embryonic development using in vitro culture method and genotoxicity assay.
P2860
Q24813384-F09DFFA6-B9D8-4BC2-8F16-10343D2EBF3EQ26995027-6C8BF145-7DC2-4E3E-8BE9-0ED90F36E2D2Q28077755-CC59777E-45BD-4BD0-BCB3-8AE474911607Q28078967-3114C764-4A61-46AA-86FF-26A3582225F6Q31099702-364B98BB-1169-40D2-8654-264FD42F11A2Q33386499-0249BB33-11EF-4165-B9C6-0B1AAA1057E3Q33789401-6A696F49-8EE3-42C6-B669-BC21DC439689Q34278856-48BF90F2-1639-41F8-B89D-312859A0BC7BQ34470423-52A28F4E-6767-4F39-92C0-5217F1A57FC9Q35821894-0C310A43-0FA3-4818-BDD1-49360BE4242CQ36063745-1D998AFB-FD21-466B-9FCD-7E9DB5C3DDF2Q36160668-D408B446-ECC5-4AE0-9243-F2579F1CCB8CQ36239522-9618CDDC-88E5-422A-8564-5DF1A760B305Q36510063-722B747B-F02A-4399-8D4E-B544A31FFC9FQ37624544-478E5D64-E4CE-4660-B8D2-A969A70E2D44Q37766083-C026F7EE-3FA7-4E13-AEDE-4D6CA32063C8Q38087496-D1DAA879-C113-463C-9A50-530DB728F006Q38116770-97E617F2-6E12-4365-BE34-23BF71E2E19FQ38137244-AE62FEE3-C9C9-4E7B-8D04-EA712EEE6156Q38261097-6B7838F3-C9B2-4B7E-B62F-34AC6224B154Q38869704-ACEF1F54-F0A6-4B83-B487-9EA587BB119DQ40902373-3EA26B83-5486-434D-B070-048AEFF69106Q41807158-6F3EA3E7-F9CB-4B50-9E6D-87862A3D62D5Q41959528-C731430C-ED28-45D5-951C-300032FCB4E9Q42387444-FC86052C-EDE3-4A08-8FB1-64BCFFEC1788Q44316593-E2485F43-86F5-4098-87FD-EF93BDE5C1D6Q47188749-EE369D1E-C99B-48A1-9951-5A8D4E3EC726Q47290768-E3F9D500-B033-486A-B91B-92E07E83CE68Q47306143-24639915-9205-42D4-A638-7F7F8A08E113Q47362437-4DD3EEA6-29AC-4A37-8D04-6B2485CE53F4Q47431339-C3ECE3FE-9652-4D28-AC1E-0B61D46BDFD2Q47448168-B25D050B-F9DC-4C28-A2C6-1E0FF763A450Q52023192-168D5429-6067-4627-9D3A-19F4259B68C7
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Comparative pharmacokinetics of LMWHs.
@ast
Comparative pharmacokinetics of LMWHs.
@en
Comparative pharmacokinetics of LMWHs.
@nl
type
label
Comparative pharmacokinetics of LMWHs.
@ast
Comparative pharmacokinetics of LMWHs.
@en
Comparative pharmacokinetics of LMWHs.
@nl
prefLabel
Comparative pharmacokinetics of LMWHs.
@ast
Comparative pharmacokinetics of LMWHs.
@en
Comparative pharmacokinetics of LMWHs.
@nl
P356
P1476
Comparative pharmacokinetics of LMWHs.
@en
P2093
Gerotziafas GT
P356
10.1055/S-2000-9497
P478
26 Suppl 1
P577
2000-01-01T00:00:00Z